mRNA vaccine: a potential therapeutic strategy

Abstract

mRNA vaccines have tremendous potential to fight against cancer and viral diseases due to superiorities in safety, efficacy and industrial production. In recent decades, we have witnessed the development of different kinds of mRNAs by sequence optimization to overcome the disadvantage of excessive mRNA immunogenicity, instability and inefficiency. Based on the immunological study, mRNA vaccines are coupled with immunologic adjuvant and various delivery strategies. Except for sequence optimization, the assistance of mRNA-delivering strategies is another method to stabilize mRNAs and improve their efficacy. The understanding of increasing the antigen reactiveness gains insight into mRNA-induced innate immunity and adaptive immunity without antibody-dependent enhancement activity. Therefore, to address the problem, scientists further exploited carrier-based mRNA vaccines (lipid-based delivery, polymer-based delivery, peptide-based delivery, virus-like replicon particle and cationic nanoemulsion), naked mRNA vaccines and dendritic cells-based mRNA vaccines. The article will discuss the molecular biology of mRNA vaccines and underlying anti-virus and anti-tumor mechanisms, with an introduction of their immunological phenomena, delivery strategies, their importance on Corona Virus Disease 2019 (COVID-19) and related clinical trials against cancer and viral diseases. Finally, we will discuss the challenge of mRNA vaccines against bacterial and parasitic diseases.

Cited by papers we hold 7

• Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment · 2024
  No notice
• Alternative splicing and related RNA binding proteins in human health and disease · 2024
  No notice
• Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders · 2024
  Corrected
• mRNA vaccines in disease prevention and treatment · 2023
  No notice
• Circular RNA vaccine in disease prevention and treatment · 2023
  No notice
• Neoantigens: promising targets for cancer therapy · 2023
  No notice
• RNA-based therapeutics: an overview and prospectus · 2022
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.